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Abstract 
Recently identified natural atropisomeric compounds with potential medicinal applications are 
presented. The ability of natural receptors to possess differential binding between atropisomers is 
an important factor when considering active and inactive atropisomeric drugs, and has required 
the development of new techniques for atropselective synthesis of desired targets. Advances in 
this field therefore have significant relevance to modern pharmaceutical and medicinal chemistry. 
The atropisomeric natural products discussed include hibarimicinone, flavomannins, 
talaromannins, viriditoxin, rugulotrosin A, abyssomicin C, marinopyrroles, dixiamycins, 
streptorubin B, ustiloxins A-F, haouamine A, bisnicalaterines, and tedarene B, all of which show 
significant potential as leads in antibiotic, antiviral and anticancer studies. The importance for the 
development of common practices regarding atropisomer recognition and classification is also 
emphasized.  
1. Introduction 
Natural products have long been a source of inspiration for medicinal chemists, with a multitude 
of current pharmaceuticals derived from traditional medicines or biological effectors. Such 
compounds elicit a targeted and measured response, thus making them an excellent stimulus in 
the design and synthesis of new therapeutics. The activities of these naturally-produced scaffolds 
are attributed primarily to the presence of specific functional groups which complement the target 
site of a protein. However, given the specific tertiary structure of proteins, the geometric 
orientation of bioactive molecules is crucial to their ability to favourably interact with active and 
allosteric sites. Thus, an understanding of the relationship between structure and activity is crucial 
in new drug development, and is of particular importance with respect to chiral compounds. 
1.1 Defining Atropisomerism 
The most widely documented category of stereoisomerism is that of central, or point, chirality, 
which generally refers to the geometric arrangement of substituents of a single carbon atom, and 
is typically designated as either an (R) or (S) configuration. Point chirality is an inherent feature in 
all biological systems; a simple and common example being amino acids (excluding glycine), 
which exist primarily in the levorotatory form. This substantiates the prevalence of 
stereoisomerism in naturally produced compounds, and the necessity that drug molecules exhibit 
an ideal geometric orientation for selective interaction with target proteins. While this end is most 
commonly achieved by control of point chirality, there exists an under-appreciated form of 






P, or (Sa)M, or (Ra)  
Figure 1: Restricted rotation about a biaryl bond, giving rise to (M) and (P) atropisomers, with alternate nomenclature of Ra 
and Sa respectively (subscript a indicating axial chirality), with highest priorities assigned to the ortho hydroxyl groups. 
Atropisomerism (from the Greek atropos, meaning ‘not turning’) refers to the restricted rotation 
of a single bond, which effectively locks the configuration into a ‘minus’ (M) or ‘plus’ (P) isomer 
(Figure 1), and in many cases may be visualised as a ‘helicity’. By definition, atropisomers must 
be fully resolvable at room temperature for ≥1000 seconds, corresponding to an energy barrier of 
23.3 kcal.mol-1 – the main distinguishing feature between atropisomers and rotamers.1 Molecules 
with significant steric congestion generally have the potential to exhibit atropisomerism, and as 
such, this phenomenon is most often observed between two ortho-substituted aryl systems; 
however, any forces which are adequate to impose a high enough energy barrier to rotation may 
give rise to atropisomers, including any attractive or repulsive forces (H-bonding, ionic 
interactions, π-stacking), or even in strained macrocyclic systems.2,3 It is important to note that 
more than one bond may be hindered to give rise to atropisomerism. Unlike stereogenicity arising 
from point chirality, which may only be altered through the breaking and reformation of chemical 
bonds, the configuration of atropisomers is governed primarily by their thermodynamic 
environment. Differing physiological environments within biological systems may therefore 
provide more specific targets for atropisomeric drugs, as they may be thermodynamically 
activated or deactivated. 
Protein structure is primarily governed by its sequence of amino acid residues, which give rise to 
intramolecular interactions that govern secondary and tertiary arrangements. As a result of these 
forces, the active site of a protein is folded into a specific conformation, which may complement a 
narrow range of substrates. The three-dimensional shape of stereogenic molecules is therefore of 
particular importance to the ability of an effector to interact with a protein. Thus, atropisomeric 
molecules may vary in binding specificity and activity, and consequently stereo-controlled 
syntheses are required in the production of potential pharmaceuticals. The past decade has seen a 
marked increase in the identification and appreciation of atropisomers as specific drug leads, 
which has driven the development of new synthetic techniques to allow the stereoselective 
generation of derivatives.3 
Given the significance of stereoisomerism and the wealth of molecular structures that natural 
product chemistry provides, there is a need to highlight the modern emphases in atropisomeric 
stereochemistry; in particular the requirement for more awareness of its existence, especially in 
emerging studies on natural products. This review is by no means a comprehensive overview of 
all natural molecules exhibiting atropisomerism. Rather, the approach has been to provide 
examples of newly emerging atropisomeric natural products, with a particular emphasis on 
systems which do not contain the ‘traditional’ biaryl axis. This being said, several traditional 
biaryls have been outlined, as they are the most well-studied examples, and offer possible 
analytical and synthetic insight into all types of conformationally restricted molecules. Although 
systematically not possible for all examples, this report also provides any additional outcomes 
reported for these systems, including (but not limited by) synthesis of stereoisomers, biological 
uses, detection and assignment of stereochemistry, and in a few cases, the biological origins of the 
molecules. Significant applications also exist for atropisomeric drugs as potential therapeutic 
agents, and as such, detection and analysis techniques are ever-improving, resulting in a greater 
understanding of the underlying principles and dynamics which govern these systems. Therefore, 
with the growing appreciation of the atropisomeric phenomenon, both in traditional biaryl 
systems and more modern cases (e.g. conformationally restricted macrocycles), presented here are 
a series of modern reports outlining both intriguing new stereogenic structures, but also advances 
in knowledge of some perennial examples of atropisomerism, showing that even famous 
examples are still be investigated with more knowledge surrounding their atropisomerism 
emerging. 
1.2 Natural Atropisomerism in Medicinal Chemistry 
There are many well-documented atropisomeric pharmaceuticals, whose utility as effective drugs 
or leads have been demonstrated, though their axial chirality is often unappreciated. Therefore, it 
is worth mentioning the almost clichéd example of bioactive atropisomerism, vancomycin – the 
well-known glycopeptide antibiotic, often used as a drug of last resort for penicillin-resistant 
bacterial infections. Discovered in 1953, it was found to be produced by soil bacteria, 
Amycolatopsis orientalis, and exhibits broad-spectrum activity against a number of gram-positive 
bacteria.4 Less appreciated is that the clinical formulation of vancomycin is exclusively the (P) 
isomer of the molecule (Figure 2, Compound 1); the highly-strained cyclophane (M) isomer 
remains undetected.5 This exclusivity also extends to the axial chirality shown by both biaryl 
ethers. The increasing instances of vancomycin resistance have hence necessitated the need for 
alternative treatments, though it is clear that this naturally-produced atropisomer has played a 
crucial role in the progression of antibiotic drugs, and has acted as a safeguard from penicillin-
resistant microbes for decades.6 
Figure 1: The structure of vancomycin B (1), the active (M)-gossypol (2), and Mbandakamine A (3), with chiral axes shown in 
red. 
Another perennial example is the toxic gossypol (Figure 2, Compound 2), a compound produced 
by the Gossypium cotton genus, which has been shown to have possible applications as an 
antifertility and anticancer agent through binding to antiapoptotic protein Bcl-XL. Even though 
this is a classic example of natural product biaryl atropisomerism, it has only recently been shown 
that the active atropisomer of gossypol is that of the (M)-(-) enantiomer.7 This atropisomeric 
configuration is an order of magnitude more potent than the (P)-(+) enantiomer, hence current 
studies are focussed on identifying plant species which preferentially produce (M) over (P) with a 
high enantiomeric excess in an attempt to reduce systemic toxicity. Thus far, the highest observed 
production was by the Thespia danis Oliv. (Malvacea), with a production ratio of 78(M):22(P).7 
Consequently, a variety of atropisomeric derivatives of the (M)-(-)-gossypol scaffold have been 
synthesized in an attempt to reduce the side-effects of the compound, of which several have 
shown enhanced activity against Bcl-XL protein.
8  
The naphthylisoquinoline alkaloids are another important class of atropisomeric natural products 
worthy of mention in these early stages. These natural products are among the best studied 
examples of atropisomers, and have been extensively investigated;9 including their isolation, 
identification, stereoselective syntheses, biological activities10 and biosynthetic origin.11 Here we 
depict one of the most recent examples reported by the Bringmann group; Mbandakamines A 
(Figure 2, Compound 3) and B (not shown), which are unsymmetrical dimeric alkaloids isolated 
from an Ancistrocladus species collected from the Congo.12  
In recent years, there has also been a creative appreciation of ‘non-traditional’ atropisomerism 
associated with diazepine moieties.13 Though these molecules themselves do not contain a 
stereogenic carbon or biaryl axis, they exhibit atropisomerism through conformational inversion 
of the non-planar ring. The diazepine moiety forms the core of a variety of natural effector 
molecules; though a variety of synthetic drugs, like benzodiazepine (Figure 3, Compound 4), are 
more widely known. The stereodynamic properties of such compounds are crucial when 
considering eutomer/distomer relationships for pharmaceutical application, requiring analysis of 
rotational energy barriers, and hence racemization rates. 
 
Figure 2: The two possible configurations of benzodiazepine (4). 
1.3 The Detection of Atropisomerism in Natural Products 
Though often overlooked, several procedures exist whereby the absolute configuration around an 
atropisomeric axis may be determined. Primarily, recognition of atropisomers comes from the 
identification of motifs particular to them, such as a substituted biaryl moiety. Detection generally 












































































electronic circular dichroism (ECD) to probe the electronic transitions of UV-active regions, 
and/or vibrational circular dichroism (VCD) to probe vibrational transitions of the IR-active 
regions.14 The ECD/VCD spectra of two atropenantiomers will appear as near-mirror images of 
each other (i.e. as opposite phases), and as such are relatively simple to distinguish between. 
However, to determine which spectrum corresponds to a particular configuration requires further 
analysis; often extensive 2D NMR techniques, however computational prediction is more routine. 
There are various ab initio methods which may be applied,15 though the most common of these 
relies on optimizing the structures of the two predicted atropenantiomers with a density functional 
theory (DFT), then applying a time-dependent (TD) perturbation to predict the vibrational or 
electronic transitions.16 Thus, the TD-DFT method calculates CD spectra, which may be 
compared to experimental spectra to confidently assign the relative atropisomerism. However, a 
number of shortcomings exist with this method, particularly in that axial chirality dominates the 
signal of CD spectra, and overwhelms any influence that stereogenic atoms may have on the 
polarized light; this means that the absolute configuration of such centres must be determined 
through other methods, such as X-ray crystallography or NOE analysis.15,17  
An understanding of the half-lives of atropisomers is also crucial if intended for pharmaceutical 
use, as one form may have undesirable effect, or may simply be inactive, giving rise to 
complications in shelf-life and dosage. Generally, such half-lives are determined using chiral 
HPLC at low temperatures, to evaluate the configurational stability of an atropisomer against 
inversion, though computational calculation of rotational energy barriers is also an effective 
technique. 
2. Recent Detection and Synthesis of Selected Biaryl Atropisomers in Natural 
Products 
2.1 Hibarimicinone: A microbial intermediate with antitumoral and antibiotic properties 
In 1997, the Oki group conducted screening of microbial products for potential protein kinase 
inhibitors, and found that a strain of Microbispora rosea, isolated from soil extracts from the 
Hibari region of Japan, contained multiple compounds with varying inhibitory activities.18 
Analysis of the microbial cellular debris identified the presence of a new class of compounds, 
which were referred to as the ‘hibarimicins’.  
This family of molecules all contain a quasi-dimeric tetracycline backbone, with the variations of 
hibarimicins A, B, C, D, and G arising from differing carbohydrate substituents (Figure 4, 
Compounds 5a-5e). UV-vis analysis, IR spectroscopy, FAB-MS, and exhaustive NMR studies 
(including COSY, HMBC, and NOE) were used to assign the relative structure of hibarimicin B,19 
and the structures of the other hibarimicins inferred from spectral comparison. Hibarimicinone 
was determined to be the aglycon precursor forming the core of the hibarimicins, with the 
structure of a polyketide with a naphthyl-naphthoquinone structure (Figure 4, Compound 5f). 
 
Figure 3: The general structure of the hibarimicin family of molecules; hibarimicins (A, B, C, D, G) R = Sugar (5a-e); 
hibarimicinone R = H (5f). 
The atropisomerism that the hibarimicin family exhibit arises from restricted rotation about the 
biaryl axis connecting rings D and E, imposed by the four ortho substituents (Figure 4). To 
elucidate the absolute configuration around this bond, a C2-symmetric shunt metabolite HMP-Y6 
– a glycosylated structural analogue of hibarimicinone – was synthesized by Romaine et al, 
utilising a biomimetic homocoupling, and two-directional bis-annulation.20 Using chiral-LC, the 
racemic mixture was optically resolved into (M) and (P) components, and using ECD spectra it 
was observed that the natural products are all exclusively in the (P) configuration. Importantly, it 
was noted that upon heating to 60 °C, hibarimicinone was found to be exclusively in the (M) 
form, indicating the thermodynamic favourability of this (M) isomer, and suggesting that the 
naturally produced (P) isomer is a kinetic product.20  
It was only in recent years that the complex natural metabolite itself was first successfully 
synthesised by Tatsuta et al.21,22 The multi-step synthesis (Scheme 1) proceeds from a 
pentasubstituted aryl system (6) by a stepwise silver-mediated oxidative dimerisation, and 
subsequent thiolactonisation to give 7. This is then converted to the axially-chiral scaffold of 
thiolactone (8) by a subsequent kinetic resolution following the installation of a chiral carboxylate 
system, which was later removed. A dual-Michael–Dieckmann cyclization with the chiral decalin 
9 furnished the fused core scaffold 10, which upon deprotection and intramolecular etherification 
gave the desired hibarimicinone (5f).21 The final yield of the native (P) atropisomer 5f was 22% 
from the enantiopure biaryl thiolactone 8, and could be quantitatively converted to the (M) form 
by heating to 60 °C in neutral methanol.22 To ensure minimal interconversion between 
atropisomers during the reaction, the reaction temperature at each step was maintained below 60 
°C.  
An alternate synthesis was reported in the same year by Liau et al, instead utilising an 
unsymmetrical two-directional double annulation on a racemic mixture of a core biaryl structure 
(i.e. both M and P forms), followed by etherification, to generate both atropisomers of 5f in 
comparable yields.23 Importantly, this group determined that interconversion between 5f and 
atrop-5f is more likely pH dependent, as heating in acidified methanol provided little change in 
atropisomer composition. The group postulated that conversion to the more stable (M) form 
required access to a deprotonated intermediate, facilitated by an environment of pH 7.5, rather 
than a strictly thermal energy threshold. Examples of natural atropisomerism such as this 
demonstrate the ability of atropisomers to interconvert between (M) & (P) isomers, which may 
prove to be a distinct advantage of atropisomeric systems in exploring active-inactive molecular 
switching. 
Scheme 1: The first synthesis of hibarimicinone (5f), with construction of the hibarimicin core by a dual-Michael-Dieckmann 
reaction of central thiolactone 8 with 9, furnishing the final product 5f after deprotection. 
In terms of the biosynthesis of the hibarimicins, it was initially postulated to most likely be 
produced by a polyketide synthase.19,24 Using 13C-labelling and blocked mutants of the TP-A0121 
strain, Oki et al demonstrated that hibarimicinone is produced via an oxidative coupling of a 
precursor monomer polyketide, which undergoes an oxidative cyclisation to generate the ether 
ring between cycles A and B, and was identified as the atropisomeric aglycone precursor to the 
other hibarimicins.25 There are ongoing studies towards a biomimetic synthesis utilising oxidative 
dimerization of the hibarimicins, though these have thus far proven unsuccessful.26 
The extracted compounds (Hibarimicins A, B, C, D and G) were screened for inhibition of 
calmodulin-dependent protein kinase III (CAMKIII), protein kinase A (PKA), protein kinase C 
(PKC), and protein tyrosine kinase (PTK). All of the natural molecules had potent PTK and 
CAMKIII inhibition, though showing little inhibition of both PKA and PKC, indicating 
specificity to the PTK protein. MIC values of PTK for the hibarimicins were around 1.8 μM, and 
1.2 μM for hibarimicinone, and the hibarimicins also displayed some degree of HL-60 cell 
differentiation. Further investigation revealed that all of the identified compounds exhibited a 
mild gram positive antibacterial inhibition, with MIC values ranging from 0.8-12.5 μg/mL.18 
Hibarimicinone was found to be the most potent tyrosine kinase inhibitor, and unlike its 
derivatives appeared to be a non-competitive inhibitor; however it was also less selective.27 The 
success of this synthetic approach allows for the generation of derivatives for drug development, 
and also provides foundations for the synthesis of other biaryl atropisomers. Hibarimicinone in 
particular has the potential for specific tyrosine kinase inhibition, though additional studies into 
potential medicinal application are required. 
2.2 Flavomannins and talaromannins: Potential novel route for antibiotic action 
The native defences of fungi and bacteria provide a significant resource in the discovery of new 
antibacterial drugs, due to highly-evolved target specificity and selectivity, which make them 
attractive prospects. Lesser-investigated sources of bioactive molecules are endophytic fungi that 
reside within both plants and marine species.28 It was recently discovered by Bara et al that the 
Talaromyces wortmannii fungus, an endosymbiont of Egyptian Aloe vera (Asphodeloideae), 
contained several bioactive atropisomeric compounds; and the group conducted extremely 
extensive studies to determine any potential medicinal application.29  
Analysis of the isolated products26 found that they were similar to that of previously-reported 
flavomannin,30 allowing for general structural assignment (Figure 5, Compounds 11 and 12). HR-
ESI/MS revealed an identical molecular composition for both compounds (C30H26O10), and near 
identical UV absorption maxima.29 Analysis of 1H and 13C spectra for the pair confirmed they are 
homodimers of atrochrysone, however HPLC separation resulted in a 3.5 minute difference in 
retention time of the two products. This suggested that the natural products must differ in either 
configuration around the biaryl axis, or the arrangement of the stereogenic elements. Four other 
products extracted had similar NMR spectra, however the complexity of these spectra, and the 
differing masses obtained from HR-ESI/MS, indicated that these were instead two pairs of 
asymmetric C7-C7ʹ linked dimers. Further analysis indicated these were heterodimers composed 
of one atrochrysone unit, and one unit of either an ether derivative of atrochrysone, named 
flavomannins C and D (Figure 5, Compounds 13 and 14), or a unit of emodin (Figure 6, 
Compounds 15 and 16), named talaromannins A and B. 
ECD analysis of the compounds resulted in three pairs of almost mirror-image spectra, suggesting 
they are atropdiastereomers. Given that the [α]D of one of the compounds matched the value 
previously reported for flavomannin A (11),30 the corresponding compound was thought to be its 
atropdiastereomer, and dubbed flavomannin B (12). Using TD-DFT (B3LYP, BH&HLYP, 
PBE0/TZVP) ECD calculation protocols, the simulated ECD spectra of both atropisomeric 
configurations matched well with the experimental ECD data, assuming identical point chirality at 
C3/C3ʹ. Thus, it was concluded that flavomannin A is the (M) atropisomer (11), and flavomannin 
B is the (P) atropdiastereomer (12).29 Using the same techniques, the axial chirality of 13 and 14 
were assigned as (P) and (M), respectively; inverted in relation to 11 and 12, as the addition of the 
methoxy to the C6ʹ alters the CIP priority assignment. Talaromannins A (15) and B (16) were also 
determined to be the (M) and (P) atropdiastereomers, respectively. However, as previously 
mentioned, axially-chiral groups such as the biaryl bond dominate the ECD spectrum, and so the 
absolute configuration of the stereogenic C3ʹ was unable to be conclusively determined. 
Previously, vibrational circular dichroism (VCD) and vibrational absorption (VA) techniques 
were successful in the identification of point chirality in the atropisomeric cephalochromin.31 This 
method relies on differences between both the calculated VCD and VA of the (M) and (P) 
diastereomers, such that by subtracting one from the other, the individual contribution of 
stereogenic atoms may be determined. However, in this case, the residual signal was negligible, 
and so no conclusive definitions of absolute configuration of the other stereogenic elements could 
be drawn. 
 
Figure 4: The determined structures of flavomannin A (11), flavomannin B (12), flavomannin C (13), and flavomannin D (14), 
with undetermined point chirality at C3 and C3ʹ. 11 and 12 are homodimers comprised of two atrochrysone moieties connected 
via the atropisomeric bond; wheras 13 and 14 are heterodimers comprised of an atrochrysone moiety (right of atropisomeric 
bond) and an ether derivative of atrochrysone (left of atropisomeric bond). 
 
Figure 5: The determined structures of talaromannin A (15), and talaromannin B (16), with unknown point chirality of C3. The 
heterodimer is comprised of an emodin moiety (left of atropisomeric bond) and atrochrysone moiety (right of atropisomeric 
bond).  
Currently, there are no reported syntheses for these specific natural products, though it is evident 
that an atropselective biaryl coupling utilising one of the many well-established techniques (see 
review by Bringmann et al)3 may be applied to such an end. The biosynthesis of these dimeric 
compounds also remains ambiguous; though related dihydroanthracenones have been reported for 
higher order plants, the pathways involved for fungal production may differ significantly, and so 
cannot be subjected to speculation. 
Potential antibacterial activity was determined by subjecting an array of both gram-positive and 
gram-negative bacteria to each compound, with the highest MIC values (4-8 μg.mL-1 for the most 
potent) observed against Staphylococci. Intriguingly, inhibitory data indicates greater 
effectiveness against multi-resistant strains of Staphylococci versus susceptible reference strains. 
Further investigation into the antibiotic action of the potential atropisomer concluded a 
bacteriostatic mode of action up to 16 μg.mL-1, and while bactericidal action may be observed at 
higher concentrations, the hydrophobicity of each of the compounds prevented testing to this end. 
This antibacterial activity may rely on the C7-C7ʹ axis connecting the two units; recently detected 
C7-C5ʹ linked regioisomers of flavomannins C and D have proven to have no parallel antibiotic 
activity.32 The cytotoxicity of all six atropisomeric natural compounds was tested using THP-1 
human leukemic monocyte cells and BALB/3T3 mouse embryonic fibroblast cells, and the IC50 
values of all were found to be >32 μg.mL-1. These values indicate minimal interference with 
eukaryotic cell growth and function at therapeutic dosages, indicating potential for specific 
antibiotic application.  
Studies were conducted to elucidate the mode of action of these derivatives using B. subtilis, and 
though no MIC values were found up to 64 μg.mL-1, a reduction in growth rate was observed. 
Reporter genes in B. subtilis were used to determine the pathway affected by the compounds, and 
it was found that the yorB promoter and RecA protein were both induced; indicative of direct 
interference with DNA structure, synthesis or processing.33, 34 It was also observed that only the 
atropisomeric products with negative ωC6ʹ,C7ʹ,C7,C8 dihedral angles, namely 12, 14, and 16, 
exhibited induction of these proteins. Additionally, phenotypic analysis of cells treated with 12, 
14, and 16 showed elongated rod-like cells; an indicator for the induction of the bacterial SOS 
pathway in response to DNA interference. However, due to the fact that all compounds (11-16) 
showed a reduction in B. subtilis growth, it was assumed that this was just one pathway through 
which inhibition occurred, and was reliant on the absolute configuration of the 
atropdiastereomers. This is promising as it evidences variable activity of therapeutic compounds 
based on their atropisomeric configuration, however the group concluded it is likely the natural 
products may have an additional, potentially novel, mode of action though this requires further 
investigation. 
2.3 Viriditoxin: Inhibition of the FtsZ protein and disruption of membrane proteins in bacteria 
Bacteria, which lack eukaryotic β-tubulin, utilise a homolog known as FtsZ during replication and 
division, which polymerizes to form the contractile ring during the initiation of cell division.35 
Thus, FtsZ represents a prime target for specific bacterial inhibition to prevent replication, while 
eliciting minimal adverse effects to the eukaryotic host. It was during a high-throughput screening 
for such an inhibitor that the utility of the otherwise ‘toxic’ viriditoxin was first appreciated.36 
Viriditoxin was first discovered from extracts of Aspergillus veridinutans in 1971, though has 
since been identified as a component of a number of fungal extracts.37,38 The initial structural 
assignment of viriditoxin by Lillehoj et al indicated the structure to be that of an 8,8ʹ-binaphtho-α-
pyrone with unassigned stereochemistry, however this structure was revised in 1990 by Kawai et 
al, after NOE spectroscopic analysis revealed the 6,6ʹ-binaphtho-α-pyrone scaffold, and CD 
analysis revealed the natural atropisomeric configuration of the biaryl axis was exclusively (M) 
(Figure 7, Compound 17).38 
 
Figure 6: The confirmed structure of the naturally produced (M)-viriditoxin (17). 
Despite this structural assignment, there was little synthetic development of (M)-(-)-viriditoxin 
until recently, when in 2011 Shaw et al successfully developed a preparative-scale, atropselective 
total synthesis, utilising a chiral µ-oxo-divanadium(V) complex to define the stereochemistry 
about the biaryl axis (Scheme 2).39 This initial publication however was quickly succeeded by a 
second-generation synthesis by the same group in 2012, reporting improved scalability, yields and 
atropselectivity.40 Principally, the synthesis of the necessary precursor to monomer 18 (Scheme 2) 
was made simpler by the elimination of large-scale tin-allylation, ozonolysis and LDA-induced 
cyclisation steps in favour of a strategy which instead utilised aspartic acid as a chiral pool 
precursor, the formation and ring-opening of a chiral oxirane with a vinyl Grignard reagent, and 
ring-closing metathesis. Additionally, the use of a larger silyl protecting group (OTBDPS, in 
place of OTIPS) assisted with stability and stereoselectivity (ratio of >95(M):5(P) [TBDPS], 
compared with 89(M):11(P) [TIPS]) upon dimerisation.  
Monomer 18 was prepared by a Michael-Dieckmann strategy, using LDA in DMPU, and 
subsequent DDQ-mediated aromatisation. The resulting ethoxymethyl-protected phenol was then 
O-methylated, and the protecting group removed using ZnBr2 and n-propanethiol. Vanadium-
catalyzed oxidative homocoupling of 18 using the novel dimetallic vanadium catalyst 19 in an O2 
atmosphere afforded the desired atropisomeric precursor of (M)-viriditoxin with high 
atropselectivity (ratio of >95(M):5(P)), and in yields of up to 87% using complex 19.39, 40 Final 
deprotection, oxidation of the alcohol terminus, and esterification furnished (M)-viriditoxin (17), 
confirmed by comparison of the optical rotation and NMR spectra of synthesised 17 with those of 
a genuine sample.39 The achievement of the synthesis of (M)-viriditoxin has allowed for 
investigations into possible medicinal applications, and importantly, it has also provided a new 
method with which to control the atropisomerism involving relatively complex molecules with 
similar binaphthopyranone structures.39, 40 
Subsequent to the initial studies of its cytotoxicity (LD50 2.8 mg.kg
-1, mouse) and activation of rat 
ATPase,37, 41 there was little more known about the bioactivity of viriditoxin until 2013, when 
Foss et al reported an MIC value of 0.63 µM against B. subtillus strain 168, and determined its 
mechanism of action. Flow cytometry and microscopy undertaken by this group identified that, 
among other previously identified ‘FtsZ inhibitors’, viriditoxin acts by dissipating the membrane 
potential of bacteria, and increasing membrane permeability; not through specific in vivo FtsZ 
inhibition.42 Both of these factors mean that neither FtsZ nor the key division protein MinD can 
bind effectively to the membrane, hence halting replication of the bacteria. As such, viriditoxin 
has been implicated in having significant antibiotic activity towards fish pathogens, which could 
prove useful in conservation and agricultural fields.43 In addition to its antibiotic effects, 
viriditoxin has also shown promise in oncological studies, displaying significant promotion of 
apoptosis and autophagy in human prostate cancer cells.44 
 
Scheme 2: Synthetic route for the atropselective synthesis of (M)-viriditoxin (17), utilising a dimetallic atropisomeric 
vanadium(V) catalyst (19) for the dimerization of the naphthopyranone monomer 18. 
2.4 Rugulotrosin A: Further antibiotics from the Penicillium genus 
In 2004, an extensive screening of Australian fungal and bacterial metabolites by Stewart et al 
revealed a species of the Penicillium fungus genus (assigned MST-F8741) contained a dimeric 
tetrahydroxanthone with antibiotic activity; rugulotrosin A (Figure 8, Compound 20).45 Analysis 
of the NMR data suggested that it was a symmetric dimer about the C2-C2ʹ axis. X-ray 
crystallography analysis of rugulotrosin A determined the relative configuration of the chiral axis; 
however the data was insufficient to definitively assign the stereogenic carbons (C6, C7, C6ʹ and 
C7ʹ), though they were determined to have a relative cis arrangement. The absolute 
stereochemistry was later determined in a more recent and extensive synthetic study by Qin et al, 
which permitted access to both atropisomers and enantiomers of rugulotrosin A.  
 
Figure 7: The determined absolute stereochemistry of naturally produced rugulotrosin A (20). 
Comparison of CD spectra from the synthesized ±(M) and ±(P) forms of 20 indicated the natural 
product was exclusively (6R,6ʹR,7R,7ʹR) with regards to the stereogenic carbons, with (P) axial 
chirality.46 A B3LYP/6-31G(d) level of theory calculated a barrier of rotation of 47.7 kcal.mol-1 
for 20; the fact no (M) atropisomer was observed following heating of 20 in toluene up to 150 °C 
for 3 h indicates the thermodynamic stability of the (P) conformation.46 
For the aforementioned atropselective synthesis of 20, Qin. et al devised a strategy utilising an 
achiral ligand in a palladium coupling of two monomer units to elicit a point-to-axial chirality 
transfer effect. As such, with synthesized iodide 21 in hand, a one-pot Suzuki dimerization in the 
presence of achiral ligand SPhos generated protected intermediate 22 in 36% yield with 
diastereomeric ratio of 75(P):25(M). These were separated by recrystallization, followed by 
deprotection in 3 M HCl/MeOH, affording both rugulotrosin A and atrop-rugulotrosin A in 85% 
each (Scheme 3). The group also used HPLC with photodiode array detection (DAD) and ESI-MS 
to determine that atrop-rugulotrosin A is not naturally produced even in trace amounts by 
Penicillium (MST-F8741), indicating the process must be highly atropselective; though no further 
biosynthetic studies have currently been reported. 
Rugulotrosin A has exhibited activities against Gram-positive bacteria, with IC50 values of 2.1 
µM for B. subtilis (ATCC 6633) and 6 µM for S. aureus (ATCC 25923); though no activity 
against the Gram-negative E. coli (ATCC 25922) or human lung (NCI-H460) and colon (SW620) 
cancer cells.46 Intriguingly, atrop-rugulotrosin A had far weaker activity; only notable for an IC50 
of 10 µM against B. subtilis (ATCC 6633). Thus, these natural products are an important example 
of how atropisomeric configuration can drastically influence the bioactivity of a molecule.  
Scheme 3: Atropselective synthesis of rugulotrosin A (20) and atrop-rugulotrosin A by Qin et al. This approach utilises point-
to-axial transfer using an achiral ligand during a one-pot Suzuki coupling of monomer 21 to generate protected dimer 22 in 
36%, with a d.r. of 75(P):25(M). These intermediates were separated using recrystallization, and following deprotection 
afforded rugulotrosin A and atrop-rugulotrosin A in 85% each. 
3. Non-Traditional Atropisomerism in Natural Products 
As part of improving the recognition of the phenomenon of axial chirality, it is important to note 
that there are multitudes of various non-traditional (i.e. non-biaryl) systems in which 
atropisomerism can exist. Many such systems are strained macrocycles, however any instance of 
hindered rotation about a bond must be acknowledged as having the potential to produce 
distinguishable atropisomers; hence, a variety of these ‘exotic’ instances of atropisomerism have 
been outlined. Also, for these systems, defining the stereochemistry often uses the terminology of 
syn/anti or cisoid/transoid, for convenience in efficiently indicating configuration. 
3.1 Abyssomicin C: A promising antibacterial for Tuberculosis 
Atropisomerism of an unusual nature was identified when the molecule abyssomicin C was 
discovered during the pursuit for viable inhibitors of enzymes involved in the p-aminobenzoic 
acid (PABA) synthesis pathway, specifically to treat tuberculosis. PABA is essential for the 
production of dihydropteroate in bacteria, a precursor for folate formation.47  
Folate cofactors are vital for the survival of all organisms, and eukaryotes have developed cellular 
transporters which allow for the importation of folate from dietary sources. Bacteria, however, 
lack these transporters, and so must synthesize it themselves; making this synthesis pathway an 
ideal target for direct and specific inhibition. Abyssomicin C itself has already been 
comprehensively reviewed by Zask et al and Savic, however its unique atropisomerism 
necessitates a brief mention here, in the pursuit of expanding recognition of this phenomenon in 
non-classical systems.48,49 
There were no known inhibitors for this stage of folate synthesis when abyssomicin C was first 
discovered, hence an assay was devised to screen for any natural compounds which may exhibit 
activity. Of the actinomycetes screened, only the extracts of Verrucosispora maris strain AB-18-
032 showed activity.47 Following chromatographic separation, mass spectral analysis, 1D/2D 
NMR techniques, and X-ray crystallography were sufficient for the determination of the absolute 
structure of abyssomicin C (Figure 9, Compound 23).47 The atropisomeric potential for this 
natural product was not initially recognised until the second successful total synthesis in 2006 by 
Nicolaou and Harrison (for first synthesis, see Zapf et al)50, which produced both abyssomicin C 
(23) and atrop-abyssomicin C (Figure 9, Compound 24).51 X-ray crystallography of the two 
revealed their atropdiastereomeric relationship, and the absolute configuration was confirmed; 23 
appeared to have a more transoid conformation between the C7 carbonyl and C8/C9 double bond 
(dihedral angle 144.8° O=C7–C8=C9), whereas 24 was found to exist in a more cisoid 
conformation (dihedral angle 26.4° O=C7–C8=C9). It was observed that the isomerism arises 
from the highly strained eleven-membered ring, and that 24 could not be converted to 23 with 
heating up to 180°C (xylene, microwave irradiation), requiring instead mildly acidic conditions 
for conversion at RT (2:1 ratio of 23/24). It was later realised that 24 is in fact the main 
abyssomicin product of V. maris AB-18-032, and that 23 is only a minor product.52  
 
Figure 8: The absolute configuration of abyssomicin C (23) and atrop-abyssomicin C (24), which may convert to 23 under 
mild acidic conditions.  
This convergent synthesis relied firstly on the generation of a TES-protected 
oxabicyclo[2.2.2]octane spirotetronate intermediate (Scheme 4, Compound 25), which was then 
elaborated over 6 steps to form intermediate 27 in 38% yield. This was subjected to ring closing 
metathesis, chemoselective oxidation – assumedly where the atropisomerism of the final product 
is defined, though this configuration could not be elucidated – and deprotection to yield 24 in 
21% over 3 steps from 27. Though concise and relatively high yielding, this synthetic approach 
has since been paralleled or superseded by alternate strategies;53 notably Bihelovic and Saicic’s 
approach, which avoids epoxide ring opening of the tetronate in the hope of higher tolerance in 
the generation of analogues for SAR studies.54-56 
 
Scheme 4: Convergent synthesis of atrop-abyssomicin (24) via connection of spirotetronate intermediate 25 with 
aldehyde 26 over 6 steps to give 27, which is subjected to ring closing metathesis, oxidation and final deprotection to 
give 24. 
In 2011, Gottardi et al treated cultures of V. maris AB-18-032 with 13C-labelled precursors and 
found that abyssomicin C is biosynthetically produced from five acetates, two propionates, and a 
glycolytic pathway metabolite.57 In the same study, whole genome sequencing and 
bioinformatical analysis was used to identify genes encoding for proteins related to abyssomicin 
C biosynthesis, with in-frame deletions of the genes used to confirm their role. Comparison with 
other biosynthetic studies of tetronate antibiotics aided in the identification of genes responsible 
for abyssomicin C biosynthesis; three genes encoding for proteins for the generation of the 
polyketide backbone (which effectively forms the macrocycle in abyssomicin C); five genes 
encoding for proteins involved in the generation of the tetronate moiety; three genes for further 
oxidative enzymes; and a variety of other genes related to import, export and packaging of the 
molecule.57 
It was noted that the structure of 23 and 24 were similar to that of chorismate, a precursor to 
PABA,58 and studies revealed that atrop-abyssomicin irreversibly binds the Cys263 of E. coli 4-
amino-4-deoxychorismate in a Michael addition, forming a sulphur-bound abyssomicin D in the 
process.47 This mechanism is attributed to the α,β-unsaturated ketone, which is not present in 
other detected abyssomicins.59 Higher activity against methicillin-resistant Staphylococcus aureus 
(MRSA) observed for 24 (MIC 3.5 μg.mL-1) over 23 (MIC 5.2 μg.mL-1) has been proposed to 
arise from differing configurations of the reactive α,β-unsaturated ketone, located either side of 
the atropisomeric bond.51 The cisoid configuration of the C7 carbonyl relative to the C8/C9 
double bond in 24 (i.e. forcing the electron rich systems closer) may increase the conjugation and 
hence reactivity of this compound relative to its atropdiastereomer. Activities against 
Mycobacterium bovis, Mycobacterium smegmatis and Mycobacterium tuberculosis have also been 
reported,60 however cytotoxicity against both HeLa and normal somatic cells for several 
derivatives of abyssomicin C was observed.54 The recently generated atrop-O-benzyl-
desmethylabyssomicin C derivative shows decreased cytotoxicity while maintaining antibacterial 
strength, and may therefore have future medicinal applications.55  
3.2 Marinopyrroles: Determination of enzymatically-imposed atropselectivity  
The omnipresent threat of bacterial resistance necessitates the exploration of novel sources for 
antibiotic agents; a growing portion of which originate from the under-utilized marine 
environment. In recent years, the marinopyrrole family of molecules have attracted significant 
attention, and have already been reviewed extensively,61,62 however the intriguing structure of 
these compounds warrants their mention in this overview of natural atropisomers. In 2008, 
Hughes C. et al isolated two metabolites from Streptomyces strain CNQ-418 (found in sediment 
near La Jolla, California) with a N,C2-linked bipyrrole structure (previously unobserved 
naturally), which were subsequently named marinopyrroles A and B (Figure 10, Compounds 28 
and 29).63 Initial attempts at structural elucidation were attempted using 2D NMR techniques, 
however these proved inconclusive. As such, X-ray crystallographic analysis of marinopyrrole B 
(29) allowed the assignment of absolute structure, and through comparison of similar CD spectral 
data between 29 and 28, the structure of marinopyrrole A was inferred.63 The exclusive M-
configuration was determined given the X-ray Flack parameter 0.03 obtained for 29; which 
showed high likelihood of an M configuration about the salicyloyl moieties. In addition to 28 and 
29, marinopyrroles C-F (not shown) were later detected, of which C-E were isolated as 
exclusively the M atropisomer, while marinopyrrole F was extracted as a racemic mixture.  
In order to further probe the activity of the marinopyrroles, and to generate a variety of 
derivatives, various synthetic approaches have been constructed.61,64-69 In all cases, these 
produced racemic mixtures of 28 and 29, and at this stage no atropselective synthesis has been 
reported. Of these, the convergent and high yielding synthesis of 28 was achieved by Kanakis and 
Sarli, who managed to make use of a previously unsuccessful Ullman coupling to establish the 
bipyrrole core under microwave-assisted conditions, utilising substrates 
 
Figure 9: The absolute structures of marinopyrroles A (28) and B (29), with their composite monomeric precursor 
monodeoxypyoluteorin (30). 
containing no halogens other than the bromine necessary for the coupling (Scheme 5, Compounds 
31 and 32).68 This afforded rac-28 in 36% yield over 3 steps from the synthesized monomeric 
units. Various manipulations to 28 and some of its synthetic precursors have allowed access to 
multiple analogues for SAR studies.64, 65, 69, 70 The first, and thus far only, synthesis of 
marinopyrrole B (29) was reported in 2013 by Cheng et al (not shown), whereby the bipyrrole 
core in this case was instead generated through alkylation of a trihalogenated pyrrole, which 
underwent further manipulations to complete a Paal-Knorr construction of the second pyrrole 
ring, a precursor which allowed for the generation of rac-29.71  
 
Scheme 5: Convergent total synthesis of racemic marinopyrrole A (28). 
The postulated monomeric precursor monodeoxypyoluteorin (Figure 10, Compound 30) was also 
isolated by Yamanaka et al, prompting further investigation of the biosynthetic pathway of the 
marinopyrroles, impressive both for its unprecedented enzymatic bipyrrole homocoupling, and the 
high degree of atropselectivity with which this aryl coupling occurs.72 Through appreciation of the 
similarities between 30 and two closely related phenylpyrrole antibiotics, pyoluteorin and 
pyrrolomycin D, and based on previous biosynthetic studies for these two compounds, Yamanaka 
et al managed to clone, sequence and isolate the gene cluster responsible for the production of the 
marinopyrroles into a minimized cosmid. The marinopyrrole biosynthetic genes, mpy1-16, were 
tested for their in vivo activities using a Streptomyces coelicolor M512 expression system. 
Through gene deletion, and analysis of 28 production via HPLC, it was determined that two 
genes, mpy10 and mpy11, both encoding FADH2-dependent halogenases, are required for the 
bipyrrole homocoupling. It was also found that the mpy12-14 ABC transporter gene cassette was 
also necessary for marinopyrrole production, assumedly for transmembrane transport of the 
molecules. Given the two tandem FADH2-dependent halogenase genes mpy10 and mpy11 were 
analogous to two found in the pyrrolomycin D synthesis gene, it was postulated that 30 undergoes 
C-3 halogenation, followed by enzymatic coupling to another non-halogenated 30 (Scheme 6, 
Route A). Yamanaka et al also proposed that halogenation of the pyrrole nitrogen in 30 could 
enable electrophilic aromatic substitution in a similar manner (Scheme 6, Route B). Given a 
distinct lack of detectable halogenated intermediates, the group concluded that these remain 
complexed with the protein until the subsequent coupling has taken place.  
 
Scheme 6: Proposed mechanisms for the enzymatic synthesis of marinopyrrole A, utilising either (Route A) C-halogenation 
and nucleophilic substitution, or (Route B) N-halogenation and electrophilic substitution. For both cases, X = a halogen (Cl, 
Br, I) 
There has been an array of reports for both antibiotic and antitumor activities of the 
marinopyrroles and their analogues, and in all studies, very little variation of activity between the 
M and P atropisomers was observed. Initial studies showed 28 and 29 had relatively low MIC90 
values against methicillin resistant S. aureus, and exhibited cytotoxic effects on HTC-116, a 
human colon cancer cell line.63 Further investigation showed (M)-28 had inhibitory activity 
against a wide range of MRSA strains and other gram-positive bacteria, as well as against the 
gram-negative Haemophilus influenza.73 However, it was found that the therapeutic window for 
28 is possibly too narrow for effective treatment, and that it is inactivated by human serum, thus 
potentially only be applicable in vivo as a topical agent.73 That marinopyrrole A has shown a high 
affinity for binding to plastic indicates a potential use as a medical instrument coating agent to 
prevent infection, with the added bonus of lowered systemic toxicity from the aforementioned 
serum inactivation.61 However, chlorinated and fluorinated derivatives have been generated 
exhibiting comparable MRSA inhibition and some resistance to serum inactivation, and thus may 
have future applications.69 Currently, the main focus of these compounds is the generation of 
derivatives for anticancer applications. Marinopyrrole derivatives with a cyclic structure and 
sulphide substituents have proven to be promising inhibitors of the interactions between pro-
apoptotic proteins, Bcl-xL and Mcl-1, and their target pro-survival protein, Bim.
64, 65, 74 It was also 
found that marinopyrrole A may restore activity of the anticancer drug ABT-737 to resistant 
cancer cells.75 As such, these atropisomeric natural products show promise for broad medicinal 
application, and studies as to this potential are ongoing. 
3.3 Dixiamycins: Atropisomeric N-C and N-N coupled dimers from marine actinomyces 
During characterisation of metabolites from marine Streptomyces, Zhang et al re-isolated the 
previously discovered xiamycin A (Figure 11, Compound 33), alongside a series of novel N-C 
and N-N linked xiamycin dimers,76 compounds also detected in parallel studies by Hertweck et 
al.77-79 Though atropisomeric N-N axes have been observed between sp2-hybridized nitrogen 
atoms in synthetic studies,80 this discovery marked the first incidence of a naturally-occurring 
atropdiastereomeric N-N axis between sp3-hybridized carbazole nitrogens. The formulae of two 
atropdiastereomeric compounds were determined to be C46H48N2O6 using HR-FAB/MS (high-
resolution fast atom bombardment), corresponding to a dimer of xiamycin A. The NMR spectra 
were also similar between the atropisomeric dimers and the monomer, however the lack of an NH 
signal in the 1H NMR spectra implied the presence of two N-N coupled dimers, allowing for 
general structural assignment (Figure 11, Compounds 34 and 35).  
To calculate the inversion rates of 34 and 35, preliminary torsion angle scans were used, and the 
two lower-energy maxima for the global scan were used as the starting geometries for transition 
state calculations. The rotational energy barriers of 34 and 35 were found to be 199 kJ.mol-1 and 
201 kJ.mol-1 respectively, consistent with experimental data showing thermal interconversion of 
the two could not be achieved even by heating at 100 °C for 1 hour.76 
Figure 10: The known structure of xiamycin A (33), and determined structures of dixiamycin A (34) dixiamycin B 
(35), and an unnamed C-N linked xiamycin dimer (36), of which both the M and P isomers were isolated.  
These extremely-stable atropdiastereomers were subjected to ECD to determine absolute 
configuration, a technique which is effective for C-C atropisomeric bonds. However, the two 
spectra did not appear as the expected mirror-images of each other; instead they were both similar 
to the ECD of 33, a phenomenon attributed to the symmetry of the 9-carbazole, the orientation of 
which is similar between 34 and 35. The main difference between the two was an intense 
absorption at 297 nm in 35, which was absent in 34. Assuming identical point chirality of the two 
dimers to the corresponding monomer, 33, TD-DFT ECD calculations were conducted for both. 
The resulting spectra displayed that an (M) configuration did not yield the observed shoulder at 
297 nm, and matched reasonably well with the ECD spectrum found for 34, which was dubbed 
dixiamycin A. Calculations for the (P) configuration did yield a similar peak at 297 nm, and was 
attributed to 35, which was subsequently named dixiamycin B.  
Concurrently, studies by Hertweck et al revealed a number of N-C linked xiamycin dimers from 
bacterial extracts, including an unnamed xiamycin dimer (36), bearing a C21-N linkage, and a 
non-atropisomeric structural isomer (dixiamycin C, not pictured) bearing a C6-N linkage.
78 
Analysis of the 1H-NMR spectrum of the unnamed dimer revealed it to be asymmetric by the 
presence of two sets of peaks, resulting in a total of eleven aromatic protons. The absence of a H21 
peak and the presence of a peak corresponding to H21' suggested a C-N linkage at C21, which was 
further supported by 1H-COSY and HMBC experiments. The absolute stereochemistry about the 
axis was determined for each compound by comparison of experimental CD spectra with a 
generated TD-CAM-B3LYP/6-31G*//B97D/TZVP spectrum. Conversely, the structure of 
dixiamycin C, bearing a C-N linkage was determined by 1H-COSY and HMBC experiments, 
however it was found to be non-atropisomeric. 
The first synthesis of dixiamycin A (34) was established by Zhang et al, by a KMnO4-mediated 
oxidative coupling N-N indole coupling of xiamycin A (33), of which 34 was selectively 
generated in trace quantities, with no 35 apparent.76 More recently, Baran et al reported a formal 
total synthesis of dixiamycin B (35) and its precursor xiamycin A (33), by the development and 
utilisation of a novel and highly chemoselective electrochemical oxidative N-N coupling.81 33 
was prepared on gram-scale over nine steps, in an overall 17% yield from chiral oxirane 37, 
which was electrochemically oxidised to afford exclusively dixiamycin B in 28% yield, in 
addition to a brominated xiamycin monomer in 17% yield, and recovered starting material (13%) 
(Scheme 7). The reason for the atropselectivity of this reaction is currently not known, and is 
complementary to that reported by Zhang. 
 
Scheme 7: Total synthesis of dixiamycin B (35) from chiral oxirane 37 by N-N dimerisation of xiamycin A (33) 
The biosynthetic origins of the dixiamycins have been the subject of several recent studies,78, 79, 82, 
83 such that there is substantial evidence that xiamycin A is derived from the sesquiterpene-bound 
indole indosespene by the action of the xia gene cluster of Streptomyces species. The exact 
mechanism for the dimerisation of xiamycin A to dixiamycins has not been fully elucidated, 
however it has been proposed that dimerisation occurs by a XiaH-mediated radical 
homocoupling.79 Preliminary antibacterial testing of 34 and 35 found greater activity against four 
indicator strains compared with that of related monomers, including 33. MIC values between 4-16 
μg.mL-1 were obtained for susceptible strains of E. coli, S. aureus, B. subtilis, and B. thuringensis. 
Though there are no current studies indicating useful pharmacological applications of the two 
atropdiastereomers, the remarkable stability of their N-N axes to acid, UV irradiation and heat 
could be utilised in the future.81 
3.4 Streptorubin B: A recently synthesized antibiotic from red pigments in Streptomyces 
The prodiginine family of molecules are produced in a wide array of bacteria and marine 
organisms, and exhibit a wide array of biological activities.84 One such member of this family was 
extracted from the pigment of several Streptomyces species in 1975 by the Gerber group using 
chromatographic techniques, and initially assigned the structure 39 (Figure 12) using mass 
spectral, UV-vis, and NMR analysis.85 A revision of this structure to 40 (Figure 12) came three 
years later by the same author,86 though confusion surrounding the correct structure and 
atropisomeric potential of the natural product remained,87,88 until relatively recent studies put any 
ambiguities to rest and confirmed the correct general structure as 40.89,90  
It was in a study by Challis et al in 2010 that NOESY correlations of the HCl salts of extracted 
streptorubin B allowed for assignment of the major naturally occurring product as being the anti-
configuration with regards to the positioning of the C7ʹ n-butyl group relative to rings A and B, 
with the syn configuration only present in minor amounts.91 Mutasynthesis with deuterium 
labelled precursors allowed the group to determine the stereochemistry of the C7ʹ in the naturally 
produced streptorubin B to be a ratio of 88:7:5 for (7ʹS, anti):(7ʹS, syn):(7ʹR, anti), respectively, 
confirmed by X-ray crystallography analysis. Importantly, Challis et al noted that reanalysis of 
the separated products following chiral HPLC did not immediately show interconversion of the 
anti (40) to the syn (41), however a mixture of the two was observed after being allowed to stand 
at RT for 7 days, indicating slowed rotation about the atropisomeric axes. 
 
Figure 11: The initial incorrect structure (butylcycloheptylprodigiosin, BCHP) attributed to streptorubin B (39), and the 
confirmed absolute structures of major natural product (7ʹS, anti) streptorubin B (40) and the minor product (7ʹS, syn) 
streptorubin B (41), with the minor (7ʹR, anti) isomer not shown. 
Parallel to this study, the first total synthesis of 40 by Thompson et al arrived at the same 
conclusion of absolute configuration.92 This investigation first utilised an approach of ring closing 
metathesis to generate the streptorubin core; however this approach failed, presumably due to ring 
strain of the desired product. Thus, a new method was developed (Scheme 8) using a Swern 
oxidation of intermediate 42 (generated from an enantioselective aldol/Wittig reaction of 
heptanedial) followed by enantioselective addition of a protected alkenyl to furnish 43. When 
subjected to KHMDS, this intermediate underwent an anionic oxy-Cope oxidative rearrangement 
to form 44, which was subjected to catalytic hydrogenation, Dess-Martin oxidation, and a Paal-
Knorr pyrrole generation to form 45, which underwent a condensation with aldehyde 46 to form 
41, which on standing converted to the presumably more stable 40, indicating that the natural 
product is the more thermally stable configuration. Using further NMR analysis, it was found that 
the ratio of equilibrated anti:syn streptorubin B at room temperature was approximately 10:1, with 
an interconversion barrier of 20.5 kcal/mol. X-ray crystallography of HCl salts for both synthetic 
and natural products confirmed the absolute configuration of the primary product as 40 using 
anomalous dispersion calculations.92  
Scheme 8: The first total-synthesis of streptorubin B, the main product being the syn isomer (41), which equilibrated over time 
to give the more stable anti configuration (40). 
The biosynthetic pathway of streptorubin B has been found to share common precursors with 
other prodiginines of similar structure.91 Using extensive biogenetic studies, Challis et al 
determined that the enzyme RedH catalyses the condensation of 2-undecypyrrole (Scheme 9, 
Compound 47) with 4-methoxy-2,2ʹ-bipyrrole-5-carboxaldehyde (48) to form an acyclic precursor 
undecylprodigiosin (49), which subsequently undergoes oxidative cyclisation catalysed by RedG 
to form streptorubin B.93 The mechanism of this oxidation had recently been determined to 
proceed through abstraction of the pro-R proton from the C7ʹ position by an Fe(III)OOH complex 
in the active site of the protein, with inversion of this C7ʹ.94  
The prodiginine family, including streptorubin B, have proven to have relatively potent 
antimalarial activity,85,95 however have too narrow a therapeutic window for direct medicinal 
application. However, some prodiginines have recently proven to have apoptotic action against a 
variety of cancer cell lines, including hepatocellular carcinoma (for which there is currently no 
effective treatment); though the extent of healthy cell DNA damage and cyctotoxicity have not 
been fully explored.84,96  
 
Scheme 9: The biosynthetic pathway of streptorubin B in Streptomyces Coelicolor A3(2). 
3.5 Ustiloxins A-F: Recent total synthesis of potent atropisomeric antimitotic agents 
Antimitotic agents are of considerable importance in the chemotherapeutic treatment of a variety 
of cancer types, as they collectively interfere with eukaryotic cell mitosis. These prevent cell 
mitosis through a variety of mechanisms, depending on the specific drug, the most prevalent of 
which is through inhibition of tubulin polymerization during the formation of microtubules.97 
Alongside well-known vinca alkaloids, some naturally-occurring peptidic molecules elicit such 
inhibition, including the atropisomeric ustiloxin family of molecules, which target the α,β-tubulin 
dimer. These cyclodepsipeptides were discovered in 1992, within deposits formed by a rice 
pathogen Ustilaginoidea virens.98 Similar in structure to the previously identified phomopsin 
family, these molecules were found to have inhibitory activity on brain tubulin,99, 100 though had 
much lower cytotoxic potential than many other antimitotic agents.101 
The recent total synthesis of the ustiloxins has allowed for SAR studies to be conducted on a 
variety of analogues, which has served the dual purpose of revealing key interactions of the 
relatively ambiguous mode of inhibition, and allowing the production of more effective 
antimitotic drugs.101,102 Ustiloxin D (Figure 13, Compound 50) was used as an initial synthetic 
target, given its simple structure and that it demonstrated the highest biological activity of all 
members of the ustiloxin family. Structurally, it is a simple cyclodepsipeptide comprised of four 
amino acid residues (namely glycine, valine, and derivatives of isoleucine and tyrosine), however 
the atropisomeric nature of the alkyl-aryl ether bond posed a number of synthetic challenges, 
including how best to selectively induce axial chirality without impacting pre-existing point-chiral 
elements, while maintaining functional group tolerance.101 The atropisomerism of this molecule 
was assigned using 1H-1H NOESY, and found to only be naturally present in the syn form. 
 
Figure 12: The absolute structure of ustiloxin D (50), as determined by NOE spectroscopy, with likely key bonds regarding 
atropisomeric nature indicated with an asterisk (*). 
The first successful approach in the generation of ustiloxin D was a linear total synthesis 
consisting of 31 steps, with an 82% yield on average for each step.103 This process, summarised 
below (Scheme 10), first required the formation of an amino alcohol (51) from ᴅ-serine in 8 steps. 
The ether (53) was then generated by nucleophilic aromatic substitution of aryl fluoride (52) with 
51. Atropselectivity about the ether is kinetically driven during the macrolactamization of 54, 
ensuring that peptide coupling can only occur in the syn configuration. With the basic scaffold 
completed, the resulting macrocycle (55) was subjected to several deprotection and 
functionalization reactions to generate ustiloxin D (50) in a 4.3% overall yield from 51.  
 
Scheme 10: Linear synthesis of Ustiloxin D (50) from protected amino alcohol 51.  
The need for further SAR studies required the development of a more tolerant synthesis which 
could accommodate variations in functionalization was needed. As such, an optimized second 
generation, convergent synthesis was devised by Joullié et al,101 and is depicted in Scheme 11. 
This modular strategy relies firstly on the phenol-mediated ring-opening of ethynyl aziridine 57, 
and subsequent deprotection and peptide coupling with a Boc-protected amino acid affords 
intermediate scaffold 58. Further deprotection of the Boc and PMB groups allows access to the 
free carboxylate and terminal amine, and EDCI-HOBt-mediated peptide coupling affords the 
macrocycle 59, of which the axial chirality is ensured by the kinetic stability of the cis 
configuration during intramolecular coupling. Finally, catalytic hydrogenation concurrently leads 
to both Bn and Cbz deprotection, and the hydrogenation of the pendant alkyne to generate the 
desired ustiloxin analogues in higher yields permitted by the aforementioned linear synthesis. 
Furthermore, this protocol allowed for simpler modulation of substituents, allowing for the 
generation of ustiloxin D, ustiloxin F, and a variety of derivatives to ascertain important structural 
characteristics for testing of inhibition of tubulin polymerization. 
Scheme 11: Convergent synthetic approach towards the generation of ustiloxin D (50), ustiloxin F (60), and a variety of 
derivatives (61-63) 
Biological testing revealed that modifications to the C6 position were generally well tolerated, as 
shown in Table 1, and also that a compacted but highly branched aliphatic unit at this position is 
most beneficial. Alterations to the phenol hydroxyl group, and inversion of the natural (9S)-
methylamino group to a (9R)-methylamino stereochemistry however resulted in total loss of 
inhibition, implying these positions are critical for tubulin binding. Though the atropisomeric 
contribution to activity has not been explored, it is crucial to recognise the importance of the 
development of synthetic techniques allowing for the production of the atropisomeric ustiloxin 
family. This natural product has given important insight into the mode of action of α,β-tubulin 
dimer inhibition, vital for oncological studies, and armed with this information, more effective 
anticancer drugs devised. 
Table 1: Inhibition of tubulin polymerization by a variety of ustiloxin derivatives with C6 modulation. 
 
3.6 Haouamine A: Natural atropisomeric alkaloid with a complex structure and synthesis  
The sheer complexity of a variety of marine natural products has provided challenging synthetic 
targets in the field of medicinal chemistry, and has historically served as impetus for the 
development of selective, efficient and scalable synthetic methodologies to allow such complex 
architectures to be targeted. The discovery of Haouamine A (Figure 14, Compound 64) from a 
species of ascidian (sea squirt)104 provided a unique molecular structure following extensive NMR 
analysis and X-ray crystallography. This structure contained a p-cyclophane moiety, a biaryl axis 
with a relatively unique, highly strained ‘bent’ benzene ring,105 and a spiro fused-ring system. The 
originally isolated molecule was observed to contain two rapidly-interconverting isomers; the 
cause for this was thought to be the result of either a slowed pyramidal inversion of the sp3 
nitrogen, or the presence of an atropisomer (Figure 14, compound 19).104 Computational 
modelling studies indicated a pyrimidal nitrogen inversion to be the more likely cause of this 
interconversion, however to confirm the configurational stability of the biaryl axis, an 
atropselective total synthesis had to be devised, which was eventually realised by Baran et al. 106 
 
 
Figure 13: The structure of Haouamine A (64) and its atropisomer (65), with the highly uncommon distorted benzene ring 
shown in blue. 
Scheme 12 demonstrates the first- and second-generation syntheses of Hauoamine A from the divergent intermediate 66, quickly 
assembled from a commercially-available indanone by a cascade annulation. Stille coupling of the 
Boc-protected polycycle (Route A), followed by deprotection and subsequent N-alkynylation 
afforded the primary foundation of the cyclophane system, and subsequent demethylation, 
peracetylation and a microwave-induced [4+2]-cycloaddition-decarboxylation afforded a racemic 
mixture of (M)- and (P)-Hauoamine A.107 Attempts at modifying the cyclophane-forming 
cycloaddition step for enhanced atropselectivity were unsuccessful, hence a second-generation 
synthesis (Route B) was devised, which instead utilised a point-to-axial chirality transfer from a 
stereogenic tether. Suzuki coupling of the boronic acid derivative of 66 (prepared from the 
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coryanthe-type monomers, linked by an aryl-alkyl or aryl-alkenyl bond. In all cases, the bridge 
between the two substructures infers an atropisomeric effect; most notably, bisnicalaterines B and 
C differ only in the stereochemistry about the axis, being the (P) and (M) isomers, respectively. 
The atropisomeric nature of bisnicalaterines A-C (67-69) in particular is unusual, as rotation is 
restricted about a point-chiral sp2-sp3 bond, resulting in both point and axial chirality at a single 
stereogenic atom. 
The divobasine structure of bisnicalaterine A was elucidated by exhaustive 2D NMR spectral 
analysis.112 Analysis of the CD spectra revealed a strong positive first Cotton effect, and a 
negative second Cotton effect, which Morita et al interpreted as inferring a right-handed helix, 
and as such, the assigned (M)-configuration. This assignment was supported by NOESY 
experiments, which showed through-space correlation of H3-H3', and between H12' and the distal 
methylene proton at H14. The corynanthe-eburnane structures of Bisnicalaterines B (68) and C 
(69) were similarly identified by extensive 2D NMR experiments, which revealed a number of 
common HMBC and COSY correlations.113 
 
Figure 14: Determined structures of bisnicalaterines A (67), B (68), C (69), and D (70), and the stereochemistry about each 
axis. 
IR spectroscopic analysis uncovered the presence of a hydroxyl group, identified as being located 
as C10', ortho to the C9' axis. The acquisition of compatible HRESI-MS spectra, and near-
identical IR spectra suggested the pair to be stereoisomers of one another. The nature of this 
isomerism was discovered by the acquisition of CD spectra for both species, which confirmed the 
pair to be atropisomers of each other, and comparison of the experimental CD spectrum with the 
calculated TD-DFT CD spectra allowed for the absolute assignment of the axes as (P) and (M) for 
68 and 69, respectively, which was supported by a number of NOESY-NMR correlations. Basic 
computational modelling of the global energy minimum conformation of each species suggested 
that the (P) isomer 68 exists in a twisted configuration, while its atropenantiomer adopts an 
extended, pseudo-linear geometry. 
Similarly to 68 and 69, bisnicalaterine D (70) was found to be composed of a coryanthe-eburnane 
scaffold by 2D NMR analysis, however the atropisomeric axis C16 was found to be oxidised, 
such that the point-chiral stereocentre had been eliminated. Analysis of the NOESY spectrum 
inferred a twisted conformation about the axis, and while no theoretical TD-DFT CD calculations 
were undertaken, comparison of the experimental CD spectrum with that of bisnicalaterine B, and 
identification of a number of similarities allowed the axis to be assigned as being the (P) isomer. 
Biological testing of these compounds revealed significant activities against a series of agonists. 
Bisnicalaterine A exhibits moderate activity against five human cancer cell lines, with IC50 values 
against HL-60, RPMI-8226, NCI-H226, HCT-116, and MCF-7 of 16.2, 31.3, 28.1, 21.9, and 38.0 
µg.mL-1, respectively.112 Bisnicalaterines B (68) and C (69) were found to have vasorelaxant 
activity, of which 68 showed a maximal relaxation of 86.6 ± 4.9% in endothelium-intact rodent 
aortic rings, which was partially attributed to the opening of K+ channels,113 however the 
complete mechanism for this activity has currently not been fully elucidated. Most interestingly, 
bisnicalaterines 67-69 each showed high potency in antiplasmodial assays against P. falciparum, 
with 67, 68 and 69 demonstrating IC50 and SI values of 4.36 µM (3.7), 1.13 µM (>47) and 0.05 
µM (>1000), respectively. The outstanding potency and selectivity of 69, compared with its 
atropisomer 68 illustrates a perfect example of the significance of atropisomerism in drug design 
and modern organic synthesis, as mediation of the axial helicity allows for enhanced activity and 
selectivity – in this instance allowing for the potency of this drug to be improved by two orders of 
magnitude.  
While there have been no attempted syntheses of this class of compounds to date, their potency 
and selectivity warrants closer investigation, dictating the need for a modular synthetic route 
which may tolerate the variety of functional groups necessary for further SAR studies. 
3.8 Tedarene B: The smallest central, planar, and axially-chiral molecule 
The development of new methods for the isolation and characterisation of cyclophane natural 
products has led to a growing appreciation of planar chirality – and as such, atropisomerism – in 
the field of natural products chemistry. Combined instances of central and axial chirality are 
known to exist, as in the previously-mentioned example of the bisnicalaterines, however the 
recent discovery of the diarylheptanoid Tedarene B (Figure 16, compound 71) from extracts of 
the widespread marine sponge Tedania ignus marked a rare example of a natural product 
containing axial, planar and point-chiral elements.115 Though Tedarene B has been briefly 
mentioned in recent reviews,116-118 its nature as a unique atropisomeric architecture, combined 
with the brevity of previous reviews warrants its mention herein.  
The diarylheptanoid scaffold is common to a number of bioactive natural products which have 
been isolated from terrestrial plant species. Sequential extraction of T. ignus with chloroform and 
methanol afforded a crude extract, which upon purification by reverse-phase chromatography and 
HPLC separation yielded Tedarene B, as well as an ether-bridged diarylheptanoid dubbed 
Tedarene A (72). While MD simulations revealed a hindered rotation about the diene, the 
rotational energy barrier for 72 was calculated to be 14.0 ± 0.4 kcal.mol-1 - falling short of the 
aforementioned requirement of a 23.3 kcal.mol-1 barrier to be defined as atropisomeric - as such 
while rotation about the diene is slowed, and may be sufficiently hindered that both conformers 
may be visible on an NMR time-scale, 72 likely exists instead as a pair of rotomers, and not as 
distinctly separable atropisomers. 
 
Figure 15: The structure of Tedarene B (71) in the native (P) configuration, and its (M) atropenantiomer (atrop-71), hindered 
by both its 10-(E) and 9-(S) stereochemistry. Tedarene A (72) was also isolated, though found to be anatropisomeric due to an 
insufficient rotational energy barrier about the diene. 
The broad structure of 71 was elucidated by a number of 2D NMR experiments and HR-ESI-MS, 
of which NMR analysis revealed an equilibrium mixture of a pair of conformers in a 4:1 ratio, 
attributed to the slow rotation of the alkene moiety. Comparison of obtained CD spectra with a 
calculated CD spectrum (TD-DFT) allowed the assignment of the biaryl axis as the (P) isomer. 
MD simulations (1500 K, 100 ns) supported this assignment, demonstrating the (P) isomer to be 
stable, while the (M) isomer was found to quickly invert to the (P) after 20-40 ns, indicating the 
(P) isomer to be thermodynamically favourable. 
The biosynthetic origins of diarylheptane scaffolds as the product of functionalisation of 
phenylpropanoids with malonyl COA are well-known.119, 120 Diarylheptanoids as a class of 
molecules have previously been identified as possessing a variety of bioactive effects,121, 122 and 
though it has been noted that cyclic diarylheptanoids have been shown to exhibit inhibitory 
activity against LPS-induced NO production,123, 124 preliminary testing indicated Tedarene B to be 
inactive. Due to the small sample size however, little further testing has been undertaken, and as 
such its efficacy as a potential therapeutic species has not yet been fully elucidated. Furthermore, 
despite its relatively small and accessible carbocyclic skeleton, no total synthesis has been devised 
as yet to allow for application toward biological testing or derivative generation. 
5. Conclusions 
Though the utility of atropisomeric natural products has been well established in recent years, 
characterization of these compounds is subject to inconsistencies in both identification and 
classification. While it is common to measure the optical activity of newly-discovered molecules, 
the source from which variations in rotation arise is not always explored. As such, rotational 
characteristics are often solely attributed to chiral centres, dismissing the effect of potentially 
atropisomeric systems. Substituted biaryl systems are relatively common throughout nature, and 
to avoid ambiguity, recognition of the contribution of atropisomers to optical activity should be 
more widely investigated. Through wider recognition of these peculiarities, the study of such 
molecules may become fully appreciable and accessible. 
This being the case, it is evident that natural atropisomerism is a valuable resource from which 
potential drug leads may be obtained, and the specificity evident in atropisomeric molecules could 
prove vital in the development of targeted therapies for almost all areas of disease. By improving 
current techniques to control the isomerism, a new realm of synthetic molecules may be explored, 
and more complex moieties may become available. 
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